EWTX Edgewise Therapeutics, Inc.

NASDAQ
$38.87

Edgewise Therapeutics, Inc. (EWTX) is expected to report earnings on February 3, 2027, before the market open. The consensus earnings estimate is a loss of $0.52 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -9.6% since its last earnings release on November 4, 2026.

Edgewise Therapeutics Beat Consensus Estimates
Wednesday, November 4, 2026 · 4:01 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 3
Wednesday · 8:00 AM ET
Earnings Whisper
-
vs ($0.52)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $41.71

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Edgewise Therapeutics Inc. is based in Boulder, United States.

Sector

Healthcare

Industry

Biotechnology

Held By 5 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.